FindTrial
Sign In

Anti-OX40 Antibody PF-04518600

BIOLOGICAL2 trials

Sponsors

University of Southern California, Laura Huppert, MD, BA

Conditions

Clear Cell Renal Cell CarcinomaInvasive Breast CarcinomaMetastatic Renal Cell CancerRecurrent Breast CarcinomaRecurrent Renal Cell CarcinomaStage III Breast CancerStage IIIA Breast CancerStage IIIB Breast Cancer

Phase 2

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
Active, not recruitingNCT03092856
University of Southern CaliforniaClear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma +1
Start: 2017-07-19End: 2026-12-31Updated: 2025-12-17
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RecruitingNCT03971409
Laura Huppert, MD, BAInvasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer +6
Start: 2019-07-08End: 2026-06-30Target: 150Updated: 2025-05-02

Related Papers

TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
Therapeutic Advances in Medical Oncology2025-01-0110 citations
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer2022-10-0152 citations
Phase II randomized double blind trial of axitinib (Axi) +/- PF-04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC).
Journal of Clinical Oncology2022-06-019 citations